Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription

Stock Track

06/05

LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.

The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.

LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1135032397"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135032397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135032397?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135032397","market":"nz","top_or_hot":-1,"title":"Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription","media":"Stock Track","content":"<p>LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.</p><p>The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.</p><p>LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LONGBIO-B Soars 54.80% Intraday on Blockbuster IPO Debut with Massive Oversubscription\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-05 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.</p><p>The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.</p><p>LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1135032397","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135032397","pubTimestamp":1780623324,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.The surge was driven by the company's highly anticipated initial public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"股票赛道|龙生物-B重磅IPO首秀获大规模超额认购盘中暴涨54.80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LONGBIO-B's stock soared 54.80% during intraday trading on Friday, marking a dramatic debut on the Hong Kong Stock Exchange.The surge was driven by the company's highly anticipated initial public offering, which saw overwhelming investor demand. The Hong Kong public offering portion was oversubscribed by approximately 4,762.58 times, with about 266,400 valid applications resulting in a one-lot winning rate of only about 2%. The IPO raised net proceeds of approximately HK$1.255 billion.LONGBIO-B is a clinical-stage biopharmaceutical company focusing on developing biologic drugs for allergic and autoimmune diseases. Its core product, LP-003, has entered eight clinical trials in China, with a Phase III trial for seasonal allergic rhinitis expected to file for market approval soon. Another key pipeline candidate, LP-005, targets complement-mediated diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}